Slideshow
Author(s):
A new study finds that the first treatment chosen to treat PAH may help mitigate the burden of all-cause cost of care.
Treatment options for PAH are evloving, yet patient prognosis remains poor. PAH also confers a heavy ecomomic burden related to cost of drugs, hospitalizations, and comorobidities. There is research that suggests initial treatment with PAH-specific medications (vs combinations of agents) may decrease healthcare utilization. Could this strategy tranlsate into reduced overall healthcare costs to treat PAH?Â